JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

CytoSorbents Corp

Slēgts

SektorsVeselības aprūpe

0.84 1.2

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.84

Max

0.84

Galvenie mērījumi

By Trading Economics

Ienākumi

3.4M

1.9M

Pārdošana

890K

9.6M

Peļņas marža

20.245

Darbinieki

149

EBITDA

-3.1M

-3.6M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+17.65% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.5M

56M

Iepriekšējā atvēršanas cena

-0.36

Iepriekšējā slēgšanas cena

0.84

Ziņu noskaņojums

By Acuity

43%

57%

124 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

CytoSorbents Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. okt. 18:41 UTC

Peļņas

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

2025. g. 24. okt. 18:31 UTC

Peļņas

Correction to Procter & Gamble to Focus on Innovation

2025. g. 24. okt. 16:25 UTC

Galvenie tirgus virzītāji

Obook Shares Rise, Company Secures New Money Transmitter Licenses

2025. g. 24. okt. 21:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. okt. 21:24 UTC

Tirgus saruna

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025. g. 24. okt. 21:07 UTC

Peļņas

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025. g. 24. okt. 20:58 UTC

Peļņas

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025. g. 24. okt. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 24. okt. 20:40 UTC

Peļņas

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025. g. 24. okt. 20:24 UTC

Peļņas

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. g. 24. okt. 20:23 UTC

Peļņas

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. g. 24. okt. 20:13 UTC

Peļņas

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 20:07 UTC

Tirgus saruna

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025. g. 24. okt. 19:40 UTC

Tirgus saruna

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025. g. 24. okt. 19:35 UTC

Tirgus saruna

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025. g. 24. okt. 19:33 UTC

Peļņas

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

2025. g. 24. okt. 19:29 UTC

Tirgus saruna

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

2025. g. 24. okt. 18:52 UTC

Peļņas

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025. g. 24. okt. 18:41 UTC

Peļņas

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025. g. 24. okt. 18:03 UTC

Peļņas

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

2025. g. 24. okt. 18:02 UTC

Peļņas

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

2025. g. 24. okt. 18:00 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

2025. g. 24. okt. 16:57 UTC

Peļņas

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

2025. g. 24. okt. 16:54 UTC

Tirgus saruna

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

2025. g. 24. okt. 16:44 UTC

Tirgus saruna
Peļņas

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

2025. g. 24. okt. 16:39 UTC

Tirgus saruna
Peļņas

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

2025. g. 24. okt. 16:33 UTC

Peļņas

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 16:23 UTC

Peļņas

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 24. okt. 16:07 UTC

Peļņas

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

CytoSorbents Corp Prognoze

Cenas mērķis

By TipRanks

17.65% augšup

Prognoze 12 mēnešiem

Vidējais 1 USD  17.65%

Augstākais 1 USD

Zemākais 1 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytoSorbents Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

1 ratings

0

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

0.705 / 0.771Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

124 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
help-icon Live chat